These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19581647)

  • 1. Angiotensin-receptor blockers in the prevention or treatment of microalbuminuria.
    Parfrey PS
    Ann Intern Med; 2009 Jul; 151(1):63-5. PubMed ID: 19581647
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
    Bilous R; Chaturvedi N; Sjølie AK; Fuller J; Klein R; Orchard T; Porta M; Parving HH
    Ann Intern Med; 2009 Jul; 151(1):11-20, W3-4. PubMed ID: 19451554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
    Chatzikyrkou C; Menne J
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1087-92. PubMed ID: 23098143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
    Scurt FG; Menne JJ; Korda A; Haller H; Chatzikyrkou C
    J Diabetes; 2020 Nov; 12(11):856-859. PubMed ID: 32755046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
    MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP).
    Ritz E
    Pol Arch Med Wewn; 2011 May; 121(5):145-7. PubMed ID: 21610661
    [No Abstract]   [Full Text] [Related]  

  • 9. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
    Mazerska M; Myśliwiec M
    Adv Med Sci; 2009; 54(1):37-40. PubMed ID: 19505872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study.
    Ritz E; Menne J; Haller H
    Nephrol Dial Transplant; 2012 Dec; 27 Suppl 4():iv28-30. PubMed ID: 23258807
    [No Abstract]   [Full Text] [Related]  

  • 11. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
    Elajami TK; Alfaddagh A; Lakshminarayan D; Soliman M; Chandnani M; Welty FK
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 14. Kidney disease in diabetology: lessons from 2008.
    Schernthaner G
    Nephrol Dial Transplant; 2009 Feb; 24(2):396-9. PubMed ID: 19144896
    [No Abstract]   [Full Text] [Related]  

  • 15. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
    Bilous R
    Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
    [No Abstract]   [Full Text] [Related]  

  • 16. [Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
    MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526676
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical inquiries. Angiotensin blockade for diabetes: monitor microalbuminuria?
    Muench J; Blenning C; Judkins DZ; Vincent C
    J Fam Pract; 2007 Feb; 56(2):145-6. PubMed ID: 17270123
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of diabetic renal disease with special reference to microalbuminuria.
    Mogensen CE; Keane WF; Bennett PH; Jerums G; Parving HH; Passa P; Steffes MW; Striker GE; Viberti GC
    Lancet; 1995 Oct; 346(8982):1080-4. PubMed ID: 7564792
    [No Abstract]   [Full Text] [Related]  

  • 19. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
    Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S;
    Hypertens Res; 2008 Apr; 31(4):657-64. PubMed ID: 18633177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration time difference of candesartin effect on albuminuria in type 2 diabetic patients.
    Shimizu H; Uehara Y; Ohsaki A; Okada S; Mori M
    Hypertens Res; 2009 Jun; 32(6):527-8. PubMed ID: 19373237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.